IDL Diagnostics (IDLDX) Q3 2025 earnings summary

Executive summary

• UBC test sales volume grew 52% year-over-year in Q3 and 24% year-to-date, while TUBEX revenues declined due to timing shifts in disease outbreaks compared to 2024.

• IFRS was adopted as the new accounting framework starting Q3 2025 to enhance transparency and comparability.

• A successful study demonstrated that TK1 and TPS biomarkers can guide treatment in advanced prostate cancer, supporting future product positioning.

Financial highlights

• Q3 net sales were SEK 11,378 thousand, down from SEK 13,996 thousand year-over-year.

• Q3 EBITDA was SEK -2,714 thousand (Q3 2024: SEK 164 thousand); net loss after financial items was SEK -3,083 thousand (Q3 2024: SEK -62 thousand).

• Gross margin for Q3 was 45.6% (Q3 2024: 57.4%).

• Cash and cash equivalents at period end were SEK 37,593 thousand (Q3 2024: SEK 44,535 thousand).

• Year-to-date net sales were SEK 36,828 thousand (2024: SEK 42,072 thousand); EBITDA SEK -9,632 thousand (2024: SEK -1,158 thousand).

Outlook and guidance

• Strong order intake for TUBEX in Q4 is expected to support a solid sales trend.

• The company aims to expand automated platform offerings and broaden its product portfolio through partnerships.

• The cancer diagnostics market is projected to grow significantly, with IDL Diagnostics positioned to benefit from increased demand for biomarkers.